The award was presented for Crystec’s modified supercritical anti-solvent (mSAS) technology for accelerated product development and chosen from shortlisted companies including 3M, Alcami, Catalent Pharma Services and Merck.
The winners of the CPhI Awards were announced on Tuesday 24 October during an awards gala in Frankfurt, Germany.
Paul Thorning, CEO at Crystec, said: “It is our great pleasure to have been recognised for our work across the industry through our expertise in crystallisation and particle engineering.”
“Our mSAS technology platform has the potential, not only to add value to product development programmes through improving the performance of medicines, but to streamline product development, reduce manufacturing costs and accelerate the route to market.”
“We are very proud of our company and of the solutions that we provide for our clients, as well as our own development programmes. We are particularly honoured to have won this award in the company of such renowned organisations.”
